VCNX
VACCINEX, INC.
$1.00
0.00%
No data for this timeframe.
Vol
Inst. Holders3 funds
Inst. Value$11.6K
Inst. Activity0 buys / 1 sells
SEC Reports1
Recent Activity
Apr 30, 2026
SEC
Vaccinex released financial results for the year ended December 31, 2025, reporting an EPS of -$1.09 for Q3 2023, which
PRESS-RELEASE — Impact 3/10
Inst.
UBS Group AG — EXIT
0 shares ($0.00)
Inst.
MORGAN STANLEY — NEAR_EXIT
4 shares ($14.00)
Apr 30, 2026
earnings
Vaccinex Reports 2025 Annual Financial Results
<p align="justify">ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCN
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $11.6K | EXIT |
| MORGAN STANLEY | $14.00 | NEAR_EXIT |
| WELLS FARGO & COMPANY/MN | $7.00 | — |
3 institutional holders with $11.6K total value (3,408 shares) as of 2024-Q3. Top holders: UBS, MORGAN, WELLS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2024-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 3,402 | $11.6K | 99.8% | EXIT -100.0% |
| 2 | MORGAN STANLEY | 4 | $14.00 | 0.1% | NEAR_EXIT -99.6% |
| 3 | WELLS FARGO & COMPANY/MN | 2 | $7.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | EXIT | 3,402 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 1,113 | 4 | -99.6% | $14.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2021-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2021-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Nov 1, 2021 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Oct 1, 2021 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Sep 1, 2021 | 3 | 3 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 30, 2026
earnings
Vaccinex Reports 2025 Annual Financial Results
<p align="justify">ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneer
Mar 30, 2026
earnings_calendar
VCNX Q4 2025 Earnings Scheduled — 2026-03-30